PL1638589T3 - Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego - Google Patents
Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianegoInfo
- Publication number
- PL1638589T3 PL1638589T3 PL04752284T PL04752284T PL1638589T3 PL 1638589 T3 PL1638589 T3 PL 1638589T3 PL 04752284 T PL04752284 T PL 04752284T PL 04752284 T PL04752284 T PL 04752284T PL 1638589 T3 PL1638589 T3 PL 1638589T3
- Authority
- PL
- Poland
- Prior art keywords
- mitoxantrone
- treatment
- multiple sclerosis
- combination therapy
- glatiramer acetate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47064003P | 2003-05-14 | 2003-05-14 | |
EP04752284.2A EP1638589B1 (en) | 2003-05-14 | 2004-05-14 | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
PCT/US2004/015225 WO2004103297A2 (en) | 2003-05-14 | 2004-05-14 | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1638589T3 true PL1638589T3 (pl) | 2014-10-31 |
Family
ID=33476729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04752284T PL1638589T3 (pl) | 2003-05-14 | 2004-05-14 | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
Country Status (11)
Country | Link |
---|---|
US (1) | US7968511B2 (pl) |
EP (1) | EP1638589B1 (pl) |
CA (1) | CA2525771A1 (pl) |
DK (1) | DK1638589T3 (pl) |
ES (1) | ES2466390T3 (pl) |
HR (1) | HRP20140524T1 (pl) |
IL (1) | IL171956A (pl) |
PL (1) | PL1638589T3 (pl) |
PT (1) | PT1638589E (pl) |
SI (1) | SI1638589T1 (pl) |
WO (1) | WO2004103297A2 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
PT1459065E (pt) * | 2001-12-04 | 2010-10-11 | Teva Pharma | Processos para a medição da potência do acetato de glatirâmero |
US20070238711A1 (en) * | 2004-05-28 | 2007-10-11 | Luanne Metz | Combination Therapy with Glatiramer Acetate and Minocycline for the Treatment of Multiple Sclerosis |
DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
EP1838326A4 (en) * | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
AU2006320162B2 (en) * | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
AU2008307565A1 (en) * | 2007-10-01 | 2009-04-09 | The Johns Hopkins University | Methods of treating neurological autoimmune disorders with cyclophosphamide |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
WO2009067690A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for safe and effective treatment using oxazaphosphorine drugs |
DE202010018377U1 (de) | 2009-08-20 | 2016-02-25 | Yeda Research And Development Co., Ltd. | Niedrigfrequente therapie mit glatirameracetat |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
WO2018178973A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4617319A (en) * | 1985-06-13 | 1986-10-14 | American Cyanamid Company | Method of treating multiple sclerosis |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
-
2004
- 2004-05-14 EP EP04752284.2A patent/EP1638589B1/en active Active
- 2004-05-14 WO PCT/US2004/015225 patent/WO2004103297A2/en active Application Filing
- 2004-05-14 DK DK04752284.2T patent/DK1638589T3/da active
- 2004-05-14 PL PL04752284T patent/PL1638589T3/pl unknown
- 2004-05-14 ES ES04752284.2T patent/ES2466390T3/es active Active
- 2004-05-14 PT PT47522842T patent/PT1638589E/pt unknown
- 2004-05-14 CA CA002525771A patent/CA2525771A1/en not_active Abandoned
- 2004-05-14 SI SI200432163T patent/SI1638589T1/sl unknown
- 2004-05-14 US US10/556,454 patent/US7968511B2/en not_active Expired - Fee Related
-
2005
- 2005-11-14 IL IL171956A patent/IL171956A/en not_active IP Right Cessation
-
2014
- 2014-06-05 HR HRP20140524TT patent/HRP20140524T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
IL171956A (en) | 2011-08-31 |
WO2004103297A3 (en) | 2005-03-17 |
DK1638589T3 (da) | 2014-06-30 |
ES2466390T3 (es) | 2014-06-10 |
SI1638589T1 (sl) | 2014-07-31 |
IL171956A0 (en) | 2006-04-10 |
PT1638589E (pt) | 2014-06-12 |
US7968511B2 (en) | 2011-06-28 |
WO2004103297A2 (en) | 2004-12-02 |
EP1638589B1 (en) | 2014-03-26 |
EP1638589A2 (en) | 2006-03-29 |
HRP20140524T1 (hr) | 2014-12-19 |
US20070173442A1 (en) | 2007-07-26 |
CA2525771A1 (en) | 2004-12-02 |
EP1638589A4 (en) | 2009-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL171956A0 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
IL180992A0 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
HRP20130622T1 (en) | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis | |
HK1073997A1 (en) | Administration of agents for the treatment of inflammation | |
HK1086488A1 (en) | Compound and use thereof for the treatment of cancer | |
AU2003220317A8 (en) | Methods and drug delivery systems for the treatment of orofacial diseases | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
AU2003300791A1 (en) | Combination therapy for the treatment of pain | |
ZA200707934B (en) | Thereapeutic formulations for the treatment of beta-amyloid related diseases | |
IL177845A0 (en) | Combination therapy with glatiramer acetate and riluzole | |
EP1575582A4 (en) | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME | |
GB0213869D0 (en) | The treatment of pain | |
IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
IL179330A0 (en) | Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis | |
IL164951A0 (en) | The treatment of pain with lfendropil | |
EP1648469A4 (en) | ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF CATATONIA | |
GB0327493D0 (en) | Treatment medicament | |
AU2003235665A8 (en) | Diagnostic and therapeutic uses of topors | |
AU2002344959A1 (en) | Use of fasl for the treatment of neurodegenerative diseases | |
AU2003217432A1 (en) | Angiopoietin-1 in the treatment of disease | |
AU2003209489A1 (en) | Medical use of captopril for the treatment and prophylaxis of cancer | |
GB0325957D0 (en) | The treatment of pain | |
SI1610785T1 (sl) | Farmacevtski kombiniran pripravek za zdravljenje spastiäśnosti in/ali boleäśine | |
AU2003293714A1 (en) | Methods for the treatment of chronic pain and compositions therefor | |
SI1613340T1 (sl) | Zdravljenje Aspergillus infekcij s timozinom alfa |